Madhavan Balachandran Sells Shares of uniQure N.V. (QURE)
Insider Madhavan Balachandran sold 10,000 shares of uniQure N.V. on June 15, 2026.
Key Points
- Madhavan Balachandran sold 10,000 shares of uniQure N.V. on June 15, 2026, with shares trading at $26.99.
- uniQure N.V., a biotechnology firm, has a market cap of $1.7 billion and a 52-week high of $71.50.
- Analysts like HC Wainwright & Co. and Chardan Capital maintain a 'buy' rating, with targets up to $50.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Madhavan Balachandran sold 10,000 shares of uniQure N.V. (NasdaqGS: QURE) on June 15, 2026. The shares were trading at $26.99 at the time of the transaction. This insider activity comes as the company continues to develop treatments for rare diseases.
Insider Buying and Selling at uniQure N.V.
On June 15, 2026, Madhavan Balachandran sold 10,000 shares of uniQure N.V. at an undisclosed price. The transaction was not planned in advance. Additionally, Jeannette Potts, Chief Legal Officer, sold 5,237 shares at an average price of $27.67 on the same day. Other insiders, including Rachelle Suzanne Jacques and Robert Gut, also made sales earlier in June.
Other Institutional Activity in uniQure N.V.
Several institutional investors adjusted their positions in uniQure N.V. AVORO Capital Advisors LLC reduced its holdings by 190,405 shares, ending with 5,959,595 shares valued at approximately $97.4 million. Aberdeen Group PLC increased its stake by 1,627,746 shares, holding a total of 5,306,386 shares worth about $86.8 million. JPMorgan Chase & Co. trimmed its position by 97,160 shares, resulting in 2,837,466 shares valued at $41.8 million. Meanwhile, Two Sigma Investments, LP grew its holdings by 1,224,587 shares, totaling 2,675,871 shares valued at $43.8 million.
uniQure N.V. Stock Down 1.1%
Shares of NasdaqGS: QURE traded near $26.99. uniQure N.V. has a market cap of approximately $1.7 billion and a forward P/E ratio that is not meaningful due to negative earnings. The stock has a 52-week low of $8.73 and a high of $71.50, with a 50-day moving average of $22.90 and a 200-day moving average of $27.22. The company has a high current ratio of 10.40 and a quick ratio of 9.97, reflecting strong liquidity, although its debt-to-equity ratio is high at 365.37.
$QURE stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its latest financial report, uniQure N.V. reported revenue of $18.1 million, showing a growth rate of 1.27%. However, the company posted a negative return on equity of -228.24% and a net margin of 0%, highlighting its ongoing financial challenges. The next earnings report is expected on July 29, 2026.
Analysts Set New Price Targets
On May 6, 2026, HC Wainwright & Co. maintained its 'buy' rating for uniQure N.V., setting a price target of $50. Chardan Capital also maintained a 'buy' rating on April 30, 2026, with a target of $37. Goldman Sachs maintained a 'hold' rating with a $10 target on April 20, 2026. The consensus among 11 analysts is a 'buy' recommendation, with an average target price of $39.11.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing gene therapies for rare and severe diseases. Its flagship product, HEMGENIX, is designed for hemophilia B patients. The company is also working on AMT-130 for Huntington's disease and other gene therapy candidates for various conditions. uniQure was founded in 1998 and employs approximately 221 people under the leadership of CEO Matthew Craig Kapusta.
Bottom Line
Madhavan Balachandran's recent sale of uniQure shares is one of several insider transactions at the company. Investors keep a close watch on insider activity and institutional changes to gauge market sentiment. As a biotechnology firm, uniQure's financial results and product pipeline developments are crucial factors for stakeholders. Analyst ratings remain optimistic, with several firms maintaining 'buy' recommendations despite the company's current financial hurdles.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.